Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

Korábbi kezelés

• History of severe bleeding tendency or coagulation disorders; clinically significant bleeding symptoms within 1 month before the first dose, including but not limited to gastrointestinal bleeding, hemoptysis (defined as coughing up or expelling ≥ 1 teaspoon of fresh blood or small blood clots, or expectorating only blood without sputum; subjects with blood-streaked sputum are eligible), or nasal bleeding (excluding epistaxis and blood-tinged postnasal drip).
• Prior treatment with systemic immunotherapy targeting tumor immune evasion mechanisms, including immune checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4, TIGIT, or LAG3 inhibitors) or immune checkpoint agonists (e.g., CD40, CD137, ICOS, OX40, GITR antibodies), or cellular immunotherapy; or prior treatment with systemic anti-angiogenic therapy (including but not limited to bevacizumab and its biosimilars, ramucirumab, endostatin, apatinib, anlotinib, etc.).
• Active central nervous system (CNS) metastatic lesions that have not shown significant symptom improvement after targeted therapy (e.g., surgery, radiotherapy). Untreated asymptomatic brain metastases (i.e., no neurological symptoms, no requirement for corticosteroid therapy, and no significant perilesional edema) are allowed.
• History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis; or evidence of active pneumonitis on chest CT during screening; or acute exacerbation of chronic obstructive pulmonary disease within 1 month before the first dose. Subjects with a history of radiation pneumonitis (which has become fibrotic) are allowed.
• History of immunodeficiency; positive test for HIV antibody; currently receiving long-term systemic corticosteroid therapy.
• Severe infection within 4 weeks before the first dose, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia.
• Major surgery or severe trauma within 30 days before the first dose, or planned major surgery within 30 days after the first dose (as judged by the investigator); minor local surgery (excluding peripherally inserted central catheter [PICC] and venous port implantation) within 7 days before the first dose.
• Concomitant diseases or medications that, in the investigator's judgment, may affect treatment compliance or patient safety during the study period.

Más betegség

• Radiologically confirmed tumor invasion of major blood vessels (e.g., aorta, central arteries/veins), vital organs (heart, trachea, esophagus, main bronchus), or encasement of major vessels with luminal stenosis. Presence of risk of esophagotracheal/pleural fistula; or pulmonary lesions with cavitation/necrosis assessed as having a life-threatening bleeding risk.
• Known active tuberculosis (TB); subjects suspected of active TB must undergo clinical examination to rule it out; known active syphilis infection.
• History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
• Known history of severe (Grade ≥ 3) hypersensitivity reaction to ivonescimab, any of its excipients, or other monoclonal antibodies.
• Any severe psychiatric or social condition that, in the investigator's judgment, may interfere with study compliance or data reliability.
• Any other condition deemed by the investigator as inappropriate for enrollment.

Laborértékek

• Known actionable driver alterations in *EGFR*, *ALK*, *ROS1*, *RET*, or other driver genes for which first-line approved therapies are available.
• Occurrence of any of the following within 6 months before the first dose: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass grafting, congestive heart failure (New York Heart Association [NYHA] Class ≥ II), cerebrovascular accident (stroke), transient ischemic attack (TIA), or arterial/venous thromboembolic events of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade ≥ 3 (e.g., pulmonary embolism, deep vein thrombosis, except asymptomatic catheter-related thrombosis); presence of severe arrhythmias requiring treatment (e.g., atrial fibrillation, supraventricular tachycardia, etc.), QTc interval prolongation (male > 450 ms, female > 470 ms), or poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg); or history of hypertensive crisis or hypertensive encephalopathy.

Egyéb

• Histological diagnosis containing small cell carcinoma or neuroendocrine carcinoma components.
• Currently participating in another interventional clinical study.
• Presence of brainstem, leptomeningeal, spinal cord metastases, or spinal cord compression.
• Pregnant or breastfeeding women.

• Voluntary participation in the study and provision of written informed consent approved by the Institutional Review Board (IRB)/Independent Ethics Committee (IEC).
• Age ≥ 18 years at enrollment, male or female.
• Histologically or cytologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) according to the International Association for the Study of Lung Cancer (IASLC) 9th edition TNM classification, and judged by the investigator as not amenable to curative surgery or definitive concurrent chemoradiotherapy.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-2.
• Life expectancy ≥ 3 months.
• Tumor tissue PD-L1 expression positive, defined as tumor proportion score (TPS) ≥ 1% (any antibody clone), as determined by a central laboratory or a qualified pathology department accredited by the study site. If PD-L1 status has not been previously tested, the subject must provide tumor tissue samples (archived or freshly obtained) obtained at or after the diagnosis of locally advanced or metastatic disease, approximately 10-15 unstained slides, for PD-L1 testing.
• Subjects with actionable driver alterations including EGFR exon 21 insertions, c-MET aberrations (amplification/overexpression/exon 14 skipping mutation), BRAF V600E, HER2, KRAS G12C, etc., for whom immunotherapy remains a primary/optional/standard first-line treatment, and who are assessed by the investigator as likely to benefit from ivonescimab, are permitted to enroll. For subjects with non-squamous histology, testing for actionable driver mutations must be performed prior to enrollment. For subjects with squamous histology, testing is recommended; if not performed, enrollment may proceed based on clinical judgment (e.g., male smokers may be exempted from testing).
• No prior systemic anticancer therapy for locally advanced or metastatic NSCLC. Subjects who have received neoadjuvant/adjuvant therapy with curative intent are eligible if the time from last treatment to recurrence/metastasis is > 6 months.
• At least one measurable lesion at baseline per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
• The treating physician has decided to initiate first-line therapy with ivonescimab monotherapy for this subject.
• Adequate organ function and reserve to tolerate the study treatment, as judged by the investigator based on clinical practice.
• Urine dipstick protein ≤ 1+ is eligible; if ≥ 2+, a 24-hour urine protein quantification must be performed and the result must be ≤ 1 g/24h for enrollment.
• Non-sterilized male subjects and female subjects of childbearing potential must agree to use effective contraceptive measures from the screening period until at least 120 days after the last dose of study treatment.